Veep in children with hodgkin’s disease - A regimen to decrease late sequelae

Obrien, Mer, Pinkerton, CR, Kingston, J, Mott, M, Tait, D, Meller, S, Radford, M, Malpas, J and McElwain, TJ (1992) Veep in children with hodgkin’s disease - A regimen to decrease late sequelae. British Journal of Cancer, 65 5: 756-760. doi:10.1038/bjc.1992.159

Author Obrien, Mer
Pinkerton, CR
Kingston, J
Mott, M
Tait, D
Meller, S
Radford, M
Malpas, J
McElwain, TJ
Title Veep in children with hodgkin’s disease - A regimen to decrease late sequelae
Journal name British Journal of Cancer   Check publisher's open access policy
ISSN 1532-1827
Publication date 1992-01-01
Year available 1992
Sub-type Article (original research)
DOI 10.1038/bjc.1992.159
Open Access Status Not yet assessed
Volume 65
Issue 5
Start page 756
End page 760
Total pages 5
Language eng
Subject 1306 Cancer Research
2730 Oncology
Abstract In an attempt to decrease the risk of second malignancies and future infertility in children with Hodgkin’s disease (HD) while retaining acceptable remission rates, an anthracycline based regimen containing no alkylating agent has been devised. VEEP contains vincristine, epirubicin, etoposide and prednisolone given at 3 weekly intervals. Forty-four patients, aged 2-15 years, have been treated: ten relapsed patients and 34 previously untreated with chemotherapy (including three relapsed stage I treated initially with radiotherapy). The median follow up for all patients is 25 months (range 6-52 months). The response rate in previously treated patients was 80% (95% CI 44-97%) and five remain alive in remission.The response rate in untreated patients was 88% (95% CI 72-97%) with 62% CR + CR(u) (uncertain/unconfirmed) (95% CI 44-77%). Of four patients who had a final response of CR(u) three have relapsed at 9, 16 and 38 months. Two of the children in CR have relapsed at 6 and 16 months. The relapse free rate at 3 years is 67% (95% CI 17-82%). In this pilot study the event free survival appears somewhat poorer than conventional combinations and further follow up is required to confirm the salvagability of relapsed patients.
Keyword Oncology
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: ResearcherID Downloads - Archived
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 11 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 04:01:59 EST by System User